Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives

Meliante, Piero Giuseppe; Petrella, Carla; Fiore, Marco; Minni, Antonio; Barbato, Christian

doi:10.3390/cimb45110577

Cited by 3 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer vaccines represent a potential alternative or adjuvant option to immune checkpoint inhibitor immunotherapy for HPV+ HNSCC. Therapeutic vaccines (which are distinct from prophylactic HPV vaccines) are designed to induce antigen-specific, cellmediated cytotoxicity that targets specific tumor antigens [132,133]. The most effectively studied antigens within HNSCC thus far are the melanoma antigen-encoding gene (MAGE), HPV-E6, E7, Epstein-Barr virus-related latent membrane protein-2, MUC-1, Wilm's tumor-1, survivin, carcinoembryonic antigen, and epidermal growth factor receptor [134,135].…”

Section: Cancer Vaccinesmentioning

confidence: 99%

“…Over 40 major trials related to therapeutic vaccines are underway for HNSCC, all of which are in various points within Phase I and II and many of which are being used in combination with immune checkpoint inhibitor agents [132]. These vaccines function via a variety of delivery platforms including autologous tumor cell vaccines, allogenic whole tumor vaccines, dendritic cell vaccines, peptide vaccines, DNA vaccines, RNA vaccines, and viral vaccines [132,133]. Of note, mRNA vaccines promise to overcome immune tolerance through neoantigen peptide targeting and several trials are underway examining their use as mono-and combination therapy with PD-1-inhibitors.…”

Section: Cancer Vaccinesmentioning

confidence: 99%

“…Of note, mRNA vaccines promise to overcome immune tolerance through neoantigen peptide targeting and several trials are underway examining their use as mono-and combination therapy with PD-1-inhibitors. mRNA vaccines can also code for antibodies, presenting a novel delivery mechanism [133].…”

Section: Cancer Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

Meci,

Goyal,

Slonimsky

2024

Cancers

View full text Add to dashboard Cite

Immunotherapy is emerging as an effective treatment for advanced head and neck cancers and interest in this treatment modality has led to rapid expansion of this research. Pembrolizumab and nivolumab, monoclonal antibodies directed against the programmed cell death-1 (PD-1) receptor, are US Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved immunotherapies for head and neck squamous cell carcinoma (HNSCC). Resistance to immunotherapy is common, with about 60% of patients with recurrent or metastatic HNSCC not responding to immunotherapy and only 20–30% of patients without disease progression in the long term. Overcoming resistance to immunotherapy is therefore essential for augmenting the effectiveness of immunotherapy in HNSCC. This review details the innate and adaptive mechanisms by which head and neck cancers can become resistant to immunotherapeutic agents, biomarkers that can be used for immunotherapy patient selection, as well as other factors of the tumor microenvironment correlated with therapeutic response and prognosis. Numerous combinations and novel immunotherapies are currently being trialed, based on better understood immune evasion mechanisms. These potential treatments hold the promise of overcoming resistance to immunotherapy in head and neck cancers.

show abstract

Section: Cancer Vaccinesmentioning

confidence: 99%

Section: Cancer Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

Meci,

Goyal,

Slonimsky

2024

Cancers

View full text Add to dashboard Cite

show abstract

Head and neck cancer: pathogenesis and targeted therapy

Liu,

Zhang,

Wen

et al. 2024

MedComm

View full text Add to dashboard Cite

Head and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, and drug resistance. The occurrence of HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, and complex genetic and epigenetic predisposition. Currently, surgery and radiotherapy are the standard treatments for most patients with early‐stage HNC. For recurrent or metastatic (R/M) HNC, the first‐line treatment is platinum‐based chemotherapy combined with the antiepidermal growth factor receptor drug cetuximab, when resurgery and radiation therapy are not an option. However, curing HNC remains challenging, especially in cases with metastasis. In this review, we summarize the pathogenesis of HNC, including genetic and epigenetic changes, abnormal signaling pathways, and immune regulation mechanisms, along with all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene therapy, epigenetic modifications, and combination therapies. Recent preclinical and clinical studies that may offer therapeutic strategies for future research on HNC are also discussed. Additionally, new targets and treatment methods, including antibody–drug conjugates, photodynamic therapy, radionuclide therapy, and mRNA vaccines, have shown promising results in clinical trials, offering new prospects for the treatment of HNC.

show abstract

Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy

Rosenberg,

Perez,

Guo

et al. 2024

Am Soc Clin Oncol Educ Book

View full text Add to dashboard Cite

The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus–specific epitopes to personalized neoantigen vaccines are ongoing with some early efficacy signals and large, randomized trials. Other novel weapons including bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibition of protumorigenic signaling pathways with emerging promising results. Finally, as with other solid tumors, ADCs remain a promising therapeutic intervention either alone or in combination with immunotherapy for patients with R/M HNSCC. With early enthusiasm across novel therapies in R/M HNSCC, results of larger randomized trials in R/M HNSCC are eagerly awaited.

show abstract

Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives

Cited by 3 publications

References 71 publications

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers

Head and neck cancer: pathogenesis and targeted therapy

Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy

Contact Info

Product

Resources

About